Given the Trump administration’s rapid succession of proposals, policy plans and regulatory developments, 2018 may well be the year of biosimilars policy.
Do coverage decisions aim to offer patients more treatment options – or drive patients to non-identical drugs based on cost alone?
EU regulators who want to encourage understanding and acceptance of biosimilar medicines might consider improving the drugs’ labels.
First came biologics, then biosimilars. And soon, explains a newly released video from The Alliance for Patient Access, patients can expect interchangeable biosimilars.
New guidance from the Food and Drug Administration directs companies on how to demonstrate a biosimilar’s interchangeability with its reference product.
There’s no way to address America’s prescription drug abuse crisis without balanced pain management, explained the National Institutes of Health’s Linda Porter, PhD, at Tuesday’s Summit on Balanced Pain Management.
f policymakers get it right, biosimilars could offer more safe and effective treatment options for patients in the coming years – potentially at lower costs.
The Food and Drug Administration may not have reached consensus on the suffixes that distinguish biological and biosimilar medications, but physicians are of one mind: Meaningful suffixes matter.
Biosimilar medicines are being prescribed more and more freely across Europe. But access to, and use of, these new medicines differs greatly depending on which European country you live in.
Patient advocates have teamed up to take an important message to European physicians and policymakers: distinct names for biosimilar medications are essential.
The Senate companion to last year’s 21st Century Cures Act could help biosimilars bypass a potential roadblock to patient access.